Skip to main content

Table 1 Baseline characteristics of the 233 patients who received radiofrequency ablation as the first-line option for hepatocellular carcinoma

From: Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance

Variable Periportal HCC(n = 56) Nonperiportal HCC (n = 177) P-value
Age (years) 59.4 ± 11.8 (37 ~ 85) 59.5 ± 9.9 (33 ~ 88) 0.966
Sex, n (%)  
 Male 43 (76.8%) 145 (81.9%)
 Female 13 (23.2%) 32 (18.1%)
Tumor size (cm) 0.190
 Mean ± standard deviation 2.9 ± 1.1 (0.9–5.0) 2.6 ± 1.1 (0.8–5.0)
  ≤ 3.0 cm 35 (62.5%) 127 (71.8%)
 3.1–5.0 cm 21 (37.5%) 50 (28.2%)
Types of electrode needles 0.107
 2-cm expandable electrode 31 (55.4%) 119 (67.2%)
 3-cm expandable electrode 25 (44.6%) 58 (32.8%)
Cirrhosis 0.579
 Yes 39 (69.6%) 130 (73.4%)
 No 17 (30.4%) 47 (26.6%)
Etiology of tumor 0.823
 Hepatitis B virus 44 (78.6%) 135 (76.3%)
 Hepatitis C virus 6 (10.7%) 15 (8.5%)
 Other 2 (3.6%) 10 (5.6%)
 No 4 (7.1%) 17 (9.6%)
Child–Pugh classification 0.700
 A 49 (87.5%) 164 (92.7%)
 B 7 (12.5%) 13 (7.3%)
Serum AFP (ng/ml) 0.38
 Mean ± standard deviation 264.7 ± 517.1 (1.82 ~ 2449.3) 229.6 ± 991.7
  ≤ 20 34 (60.7%) (1.10 ~ 9346.9)
 >20 and<400 12 (21.4%) 106 (59.9%)
  ≥ 400 10 (17.9%) 50 (28.2%)
21 (11.9%)
TACE before RFA 0.821
 Yes 37 (66.1%) 114 (64.4%)
 No 19 (33.9%) 63 (35.6%)